دورية أكاديمية

Use of salmeterol with and without concurrent use of inhaled corticosteroids and the risk of asthma-related hospitalization among patients with asthma.

التفاصيل البيبلوغرافية
العنوان: Use of salmeterol with and without concurrent use of inhaled corticosteroids and the risk of asthma-related hospitalization among patients with asthma.
المؤلفون: Meng-Ting Wang, Grant H. Skrepnek, Edward Armstrong, Duane L. Sherrill, Robin B. Harris, Cheng-Liang Tsai, Daniel C. Malone
المصدر: Current Medical Research & Opinion; Mar2008, Vol. 24 Issue 3, p859-867, 9p
مصطلحات موضوعية: ANTIASTHMATIC agents, ASTHMA treatment, ANTIALLERGIC agents, RESPIRATORY agents, CORTICOSTEROIDS, HOSPITAL patients, ASTHMATICS
مستخلص: Rationale: Studies evaluating the safety of salmeterol are inconclusive, which might be the result from not taking into account the impact of concomitant inhaled corti costeroids (ICS).Objective: To study whether salmeterol use with and without concomitant ICS, respectively, was associated with an increased risk of asthma-related hospitalizations among patients with asthma.Methods: A case-control study nested within a cohort of patients with asthma, identified in the year 2000, over a 2-year period was conducted. Cases were subjects who had a first-time hospitalization for asthma in the year 2001, and were matched with up to five controls by age (± 5 years), sex, and number of asthma-related outpatient visits.Measurements: Hospitalizations and medication use were extracted from the MEDSTAT's MarketScan database.Main results: There were 333 cases of asthma-related hospitalizations and 1607 matched control subjects. Any use of salmeterol with concomitant ICS use during the prior year was associated with a 32% risk reduction for being hospitalized due to asthma (OR = 0.68; 95% CI = 0.48, 0.96). In the presence of concomitant ICS use, patients who either used salmeterol currently or used seven or more canisters of salmeterol during the prior year had 46% (OR = 0.54, 95% CI = 0.32, 0.92), and 59% (OR = 0.41, 95% CI = 0.21, 0.79) reductions in the risk of hospital admissions for asthma, respectively.Limitations: Though indirect measure of asthma severity was adjusted during the analyses, the lack of information on lung function might result in a selection bias. Additionally, only a small sample size of patients was found to use salmeterol without concomitant ICS use, and this introduced the issue of lack of power.Conclusions: Use of salmeterol in conjunction with ICS is associated with a decreased risk of hospital admission for asthma. [ABSTRACT FROM AUTHOR]
Copyright of Current Medical Research & Opinion is the property of Taylor & Francis Ltd and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
قاعدة البيانات: Complementary Index
الوصف
تدمد:03007995
DOI:10.1185/030079908X273020